ENLV
Enlivex Therapeutics Ltd.
1W: -1.9%
1M: -2.9%
3M: +22.3%
YTD: +35.1%
1Y: -8.9%
3Y: -71.6%
5Y: -92.8%
$1.02
-0.06 (-5.56%)
After Hours: $1.12 (+0.10, +9.80%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$24.8M
52W Range0.66-2.1
Volume223,353
Avg Volume358,394
Beta1.64
Dividend—
Analyst Ratings
Company Info
CEOOren Hershkovitz
Employees71
SectorHealthcare
IndustryBiotechnology
IPO Date2014-07-31
Websiteenlivex.com
14 Einstein Street
Ness Ziona 7403618
IL
Ness Ziona 7403618
IL
972 8 662 3301
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Latest News
12 Health Care Stocks Moving In Monday's After-Market Session
Crypto Treasury Stocks Slide 62% as $2 Trillion Crypto Rout Tests Holders
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Murray Michael Antho | S-Sale | 56,390 | $2.78 | 2015-10-09 |
| WEATHERSON HARVEY D | A-Award | 12,000 | $1.25 | 2008-01-02 |
| RANEY DENNIS R | A-Award | 12,000 | $1.25 | 2008-01-02 |